2-methoxyestradiol has been researched along with erlotinib hydrochloride in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heinonen, T; Huttala, O; Mannerström, M; Sabell, E; Sarkanen, JR; Toimela, T; Ylikomi, T | 1 |
| Chen, Z; Guo, H; Hu, W; Jiao, M; Jin, T; Li, Y; Lu, M; Ni, J; Wang, Z; Wu, H; Yang, Y; Yao, Y; Yuan, A; Zhang, H; Zheng, S | 1 |
2 other study(ies) available for 2-methoxyestradiol and erlotinib hydrochloride
| Article | Year |
|---|---|
Intra-laboratory validated human cell-based in vitro vasculogenesis/angiogenesis test with serum-free medium.
Topics: 2-Methoxyestradiol; Adipose Tissue; Aspirin; Cells, Cultured; Culture Media; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Estradiol; Human Umbilical Vein Endothelial Cells; Humans; Laboratories; Levamisole; Mannitol; Methimazole; Neovascularization, Physiologic; Reproducibility of Results; Serum; Stromal Cells; Teratogens; Toxicity Tests; Umbilical Cord; Vascular Endothelial Growth Factor A | 2017 |
2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop.
Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA-Binding Proteins; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Neoplasm Transplantation; RNA-Binding Proteins; Signal Transduction; Transcription Factors | 2021 |